Extended Data Fig. 5: IL-23 pathway is the most upregulated in the tumour after castration.
From: IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
a, Gene expression of selected genes determined by NanoString nCounter gene expression assay in sham PtenPC−/− and CTX PtenPC−/− tumours. Data are shown as pool of n = 5. b, Analyses of the conditioned medium of bone marrow-derived MDSCs tested for the indicated soluble molecules by Mouse CytokineMAP B version 1.0. The graph shows the concentration of the indicated soluble molecules as log10 of the concentration found in the conditioned medium of BM-MDSCs, the values were subtracted of the background (culture medium). Data are shown as pool of n = 10. c, qRT–PCR analyses of the indicated genes in sham (n = 6) and CTX (n = 6) PtenPC−/− tumours. Data are mean ± s.e.m. of biological independent animals. Statistical analyses (unpaired two-sided Student’s t-test): *P < 0.05. d, Protein level of CXCL1, CXCL2 and CXCL5 in CTX PtenPC−/− tumours. Data are analysed as ratio between CTX (pool of three samples) and sham (pool of three samples) PtenPC−/− tumours and reported as fold increase in protein level. e, f, IL-23R protein level analysed by flow cytometry and western blot on TRAMP-C1 cells under normal culture conditions (FBS) or androgen-deprivation culture conditions (charcoal-stripped FBS). n = 4 biological independent samples per group. f, Numbers indicate fold change in protein level. Loading control: anti-β-actin antibody. The western blot was validated at least twice. g, Protein profile of the plasma of patients with CSPC and CRPC. Data are analysed as ratio between CRPC (pool of 18 samples) and CSPC (pool of 17 samples) and reported as fold increase in protein level.
